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1. Introduction 
A number of effects attributable to changes in con- 
formation have been described to occur upon the 
interaction of specific antibody with wild type and 
mutant 13-galactosidases. These effects range from 
stabilization under normally denaturating conditions 
[1 ], to disruption of the quaternary structure [2], 
facilitation of co-complementation [3], and activation 
of missense mutant gene products [4]. The latter can 
be regarded as the repair of the damage induced by a 
minor genetic defect, the substitution of a single 
amino acid in a polypeptide chain of 135,000 daltons. 
The repair of a more severe genetic defect is described 
in the present paper: it deals with the antibody- 
mediated activation of the deletion mutant product 
M15. This 13-galactosidase lacks 30 residues (AA 11-42) 
in the N-terminal region, is a dimer instead of tetramer, 
and has been well characterized asan acceptor in 
a-complementation [5]. 
2. Materials and methods 
2.1. Diluents and chemicals 
Buffer B was used for the dilution of the enzyme 
in all experiments of activation; it contained 10 mM 
(hydroxymethyl)aminomethane (tris),10 mM MgC12, 
0.1 M NaC1 and 0.05 M 2-mercaptoethanol; its pH 
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was adjusted to 7.2 (23°C) with acetic acid; the com- 
plete buffer was prepared aily by adding mercapto. 
ethanol to the stock salt solution. Buffer Hepes 0.1 M 
was used for all experiments of complementation; its 
pH was adjusted to 7.2 with concentrated NaOH. 
Thiophenyl-ethyl-/3-D-galactopyranoside (TPEG) was 
a gift from Dr. Agn~s Ullmann, Institut Pasteur. o-Nitro- 
phenyl-~-D-galactopyranoside (ONPG) was purchased 
from Mann Research Labs., Inc. 
2.2. Extraction of ~-galactosidase (fl-gal} and M15 
protein 
The ~:coli constitutive mutant 3300, grown in tryp- 
tone-lactate broth, was used for the production of 
normal/3-D-galactosidase. Th  deletion mutant 
3000-M 15 [6], was the source of a acceptor. 
Procedures followed for extraction of the enzymes 
were similar to those described by Celada et al. [7]. 
The purification of 13-gal yielded a preparation with a 
specific activity of ~500,000 EU/mg, which showed 
only minor contaminants in SDS acrylamide lectro- 
phoresis, while M15 was used as a crude bacterial 
extract. 
2.3. Assay of ~-galactosidase 
The enzymatic assay was done at 37°C in a 2 ml 
volume of buffer B containing 3 mM ONPG; the 
reaction was stopped by adding 0.5 ml of 1.2 M 
Na2CO3, and its optical density at 420 nm was 
measured and converted to o-nitrophenol concentra- 
tion using a molar extinction coefficient (1 cm path- 
way) of 4700. An enzyme unit (EU) is defined as the 
amount of 13-galactosidase which hydrolyzes 10 -9 
moles of substrate/min u der the above conditions. 
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2.4. Animals and immunization procedures 
Male and female rabbits weighing 2-3  kg each were 
used. Immunization was done by injecting into the 
foot pad 1 ml of buffer containing 3-5 mg/3-gal 
protein, emulsified with 1 ml of Complete Freund's 
Adjuvant. Some procedures were repeated for secon- 
dary stimulation and one week after challenge bleed- 
ings were done by puncturing the central artery of the 
ear. Collected serum was kept at -30°C in small 
samples after sterilization by filtration through 
millipore. 
2.5. Preparation of peptides for complementation 
Seven mg of/3-gal were dissolved in 2 ml 8 M urea 
(previously deionized), 0.25 ml 3 M Tris-acetic acid 
buffer (pH 8.6), 0.1 ml EDTA 5% and 0.025 ml 
2-mercaptoethanol. The solution was kept in the dark 
for 4 h under nitrogen atmosphere, then aminoethy- 
lation was performed at room temperature according 
to Raftery and Cole [8] with the following schedule: 
three aliquots of 0.2 ml ethylenimine were added at 
time 0, 10 rain and 20 min. At 30 min the reaction 
was stopped by slowly adding 1 ml glacial acetic acid, 
while lowering the temperature to 0°C. The mixture 
was dialyzed for 72 h,against 20% acetic acid and 
finally lyophilized. On this material, CNBr cleavage was 
performed according to Steers et al. [9] : the sample 
was resuspended in 3 m170% formic acid, and a 50- 
fold excess (with respect of the methionine residues 
present) of crystalline !CNBr (Eastman Organic Chemicals) 
was added. The reaction was allowed to proceed at 
room temperature for 24 h in the dark; then the 
reaction mixture was diluted ten-fold with distilled 
water and lyophilized. 
The peptide mixture~was u ed in complementation 
experiments without further purification and will be 
hereafter designated as 'a peptides'. The dry material 
was dissolved in 70% formic acid, and 25/11 aliquots 
thereof or of a further dilution in the same solvent 
were placed in the tubes where the complementation 
reaction was to take place; the liquid was evaporated 
under vacuum at room temperature. The dry peptides 
were resuspended in 0.1 ml of Hepes buffer. 
2.6. Activation of M15 by antibody 
A fixed concentration of M15 crude extract in 0.1 ml 
of buffer B was mixed with 0.1 ml of buffer B and 
0.1 ml of scalar antibody concentrations. The mixture 
was incubated at 28°C for 3 h, and then assayed for 
enzyme activity. 
2.7. a-complementation procedure 
0.1 ml of M15 crude extract (or a dilution thereof 
in buffer B was mixed with 0.1 ml of buffer B and 
0.1 ml of buffer Hepes containing the chosen concen- 
tration of the peptides preparation, dissolved from the 
lyophilized stock solution (see: preparation of peptides). 
The mixture was incubated at 28°C and, where not 
indicated otherwise, was assayed for enzymatic acti- 
vity after 2 h. When the effect of antibody on comple- 
mentation was investigated the 0.1 ml of buffer in the 
mixture was substituted with the chosen concentra- 
tion of antiserum. 
3. Results 
Figure la shows the effect (in terms of specific 
enzyme activity), of 1 h incubation of scalar amounts 
of anti/3-gal antiserum with a constant amount of 
M15 extract. The catalytic activity increases with 
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Fig.lA. Activation of Mr5 by increasing concentrations of 
antibody. Ordinate: enzymatic activity expressed as EU/mg 
M15 crude extract. Abscissa:/zl antibody added. (o - -o)  Whole 
anti 13-gal antiserum. (~,__A) Monovalent Fab fragments 
obtained from the same antiserum. Fig.lB. Complement- 
ation of M15 by increasing concentrations of c~-peptides. 
Ordinate: same as Fig.lA in a different scale. Abscissa: 
#g peptides added to M15. 
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antibody concentration to reach a maximum; then it 
decreases in antibody excess. The two curves shown 
indicate that this pattern is similar for native anti- 
body and for monovalent Fab fragments obtained 
from the same antiserum. 
For comparison, the enzyme activity resulting 
from a complementation f the M 15 extract in the 
presence of increasing amounts of peptides obtained by 
CNBr cleavage of wild type fl-galactosidase is plotted 
in fig.lb Since the same M15 extract was used for 
antibody activation and a-complementation the data 
are directly comparable and show that about 15% of 
the maximum activity attainable by complementation 
is obtained by antibody-M15 interaction. 
Several three-component experiments were done to 
determine the effect of anti/3-gal antibody on the 
a-complementation reaction. Table 1 shows the enzyme 
activity at equilibrium observed when three concen- 
trations of peptides and three concentrations of anti- 
bodies were mixed in all combinations with the M15 
extract. The results van be described as follows: (a) 
At low ('1') and optimal ('16') activating antibody 
concentration there is simple additivity of antibody 
and ct peptides effects, when a peptides concentration 
is low ('1') or medium ('8'), (b) At high antibody 
concentration there is depression of activity in all 
combinations. The extent of this depression reaches 
~65% of the maximum activity for all peptide concen- 
trations as well as in the absence of peptides. (c) 
When a is high ('128'), which in our conditions is 
saturating, there is a significant depression even at 
'optimal' ( '16') antibody concentration. 
The effect of anti/3-gal antibodies on the kinetics 
of a-complementation was studied by measuring the 
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Fig.2. Effect of antibody on the kinetics of a-complementation. 
Ordinate: enzymatic activity. Abscissa: reaction time. (o--o) 
M15 + anti #-gal antibody. (o--o) M15 + a peptides. (A--A) 
M15 + #-gal + a peptides. The concentration f antiserum 
corresponds to optimal activation. The concentration f 
peptides i  100-fold lower than at required for saturation. 
enzyme activity at given times after mixing M15 pro- 
tein with (i) a peptides, (ii) antibody and, (iii) ~ pep- 
tides and antibodies. Figure 2 shows the results. There 
is a significant increase of activity during the early stages 
of complementation in experiment (iii). This increases 
about 100% the sum of activity of (i) and (ii) at 
60 min, and about 30% the same sum at 180 rain. 
At 300 min the activity in (iii) is only 7% higher than 
the sum of (i) and (ii). 
4. Discussion 
Table 1 
Effect of different combinations of anti ~-gal antibodies and 
a-peptides on the activity (EU]10 -~ mg) of a fixed quantity 
of M15 
.~ Relative antibody concentration 
0 1 16 128 
8 
= 0 < 1 5 120 25 
8 
1 18 28 140 23 
8 220 250 340 170 
~ 128 2000 2000 1600 700 
Among several effects of antibodies on the confor- 
mation and the function of/3-galactosidases, the present 
one is the first involving reactivation of a molecule 
that lacks a considerable part (30 AA) of the primary 
structure. Even on the basis of the present data 
obtained with a crude preparation of M 15 it is 
possible to reach a number of  provisional conclusions. 
First, the activity brought about by antibody is a 
relatively small proportion of that obtainable by 
a-complementation (10-15%). Since the latter is 
known to activate M15 almost quantitatively, this 
means that either all M 15 reach at best 10% of the 
wild type activity or, possibly, only one out of ten 
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M15 molecules are fully active after interaction with 
antibody. 
Second, the activation of M 15 by antibody is a 
complex phenomenon, as suggested by the distinct 
peak in the antibody dose-response curve, contrasting 
with ~-complementation [1 O] and the antibody- 
mediated activation of point mutant/3-galactosidases 
[11 ], both of which are described by parabolic satur- 
ation curves. The peak of activity and the following 
depression in antibody excess cannot be interpreted as 
phenomena related to lattice formation, since the 
same patterns are observed with monovalent Fab frag- 
ments. Instead, it is tempting to attribute activation 
and depression to the presence in the anti/3-gal serum 
of at least two different antibodies capable of binding 
M15 and endowed with competing properties, and 
reaching its effective concentration at a different 
dilution of the antiserum. This hypothesis i streng- 
thened by the finding of antibodies causing inhibition 
of the wild type enzyme activity [2]. An alternative 
possibility is that the same antibody may cause 
opposite ffects in the enzyme function depending 
on the number bound per enzyme polymer. In order 
to decide between these alternatives it will probably 
be necessary to purify 'clonal" antibodies and assess 
their activating-inhibiting activity. However, the fact 
that also a-complementation can be partially inhibited 
by antibody, and that this can take place even at the anti- 
serum concentration that corresponds to the antibody 
mediated activation peak, seems to favor the first 
hypothesis. 
To evaluate the effect of antibody on the comple- 
mentation process one must recall the recent finding 
[3] that anti/3-gal enhances 5 -20  times the yield of 
c~-complementation without visibly changing the 
kinetics of the reaction. The present data differ from 
these in more than one way. In fact they show a sig- 
nificant increase in the speed of enzyme activation, 
not accounted for by summation of complementation 
and activation, but lack of any increase in final yield 
of enzyme activity. It should be noted that another 
difference between a- and co-complementations is the 
susceptibility of the latter but not of the former to be 
facilitated by substrate analogs [12]. 
The kinetics of a-complementation has been recently 
analyzed using pure reagents. After binding of the 
pure a peptide by pure M15 dimers, a tetrameric 
enzyme is formed (Langley and Zabin, personal 
communication). Collaborative xperiments are now 
in progress te determine the effect of the antibody on 
the quaternary structure of M15. 
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